Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Tesamorelin Explained: Research, Evidence & Dosage Guide

Tesamorelin Explained: Research, Evidence & Dosage Guide

Jun 11, 2026 4 min Growth Hormone
TL;DR
Tesamorelin is a synthetic copy of a hormone your brain naturally makes to trigger growth hormone release. It was FDA-approved in 2010 specifically to reduce excess abdominal fat in HIV patients with lipodystrophy. Multiple clinical trials confirm it significantly cuts visceral (deep belly) fat, and newer research is exploring its effects on liver fat and metabolic health.

What Is Tesamorelin?

Your brain makes a chemical called growth hormone-releasing hormone (GHRH). Its job is simple: tell the pituitary gland to release growth hormone (GH). Tesamorelin is a lab-made version of that signal — a synthetic analogue, meaning it mimics the natural molecule closely enough to trigger the same response.[3]

Unlike injecting growth hormone directly, tesamorelin nudges your own body to produce GH naturally. That's an important distinction. The result is a more controlled, pulsed release rather than a flood of artificial hormone.[5]

The FDA approved tesamorelin in November 2010 under the brand name Egrifta — making it the first and, at that time, only approved treatment for reducing excess abdominal fat caused by HIV-associated lipodystrophy.[3]

What Is HIV-Associated Lipodystrophy?

Lipodystrophy means abnormal fat distribution in the body. People living with HIV — especially those on older antiretroviral drugs — can develop a distinctive pattern: fat accumulates deep in the belly (called visceral adipose tissue, or VAT) while the arms, legs, and face lose fat. It's not just a cosmetic issue. Excess visceral fat is linked to heart disease, insulin resistance, and poor quality of life.[6]

This is the problem tesamorelin was designed to address.

What Does the Research Show?

It Reduces Deep Belly Fat

Two Phase 3 clinical trials — the gold standard in drug research — tested tesamorelin at 2 mg injected under the skin once daily. After 26 weeks, participants showed significant reductions in visceral fat area and waist circumference compared to placebo.[6] Importantly, patients who kept taking it through 52 weeks maintained those improvements — but fat came back when they stopped.[5]

Body image scores also improved, which matters because the physical changes from lipodystrophy can seriously affect mental health and self-confidence.[5]

It Works With Modern HIV Drugs Too

Those original trials were done before a newer class of HIV drugs called integrase inhibitors (INSTIs) became the standard of care. INSTIs are now what most people with HIV take — but they're linked to weight gain and fat changes of their own. So researchers asked: does tesamorelin still work alongside these newer drugs?

A 2024 randomized, double-blind trial answered that question. Among 38 people with HIV on INSTI-based regimens, those taking tesamorelin for 12 months saw significant reductions in visceral fat (median decrease of 25 cm²), liver fat fraction, and trunk-to-limb fat ratio compared to those on placebo. Blood sugar control was not worsened.[2] That's reassuring, because elevated blood glucose is a known concern with growth hormone therapies.

Liver Fat — An Emerging Area

That same 2024 trial enrolled people with metabolic dysfunction-associated steatotic liver disease (MASLD) — a condition where fat builds up in the liver. Tesamorelin reduced hepatic (liver) fat fraction significantly versus placebo.[2] This is an early but exciting finding, and researchers are paying close attention.

Is It Safe?

Across trials, tesamorelin was generally well tolerated. Serious adverse events occurred in fewer than 4% of patients over 26 weeks.[5] The most common side effects were injection-site reactions and effects typical of growth hormone activity — joint aches (arthralgia), headache, and mild fluid retention (peripheral oedema).[5]

Importantly, studies found no significant elevations in liver enzymes and no clinically apparent liver injury linked to tesamorelin use.[1] Glucose levels were monitored carefully across studies, and no meaningful worsening of blood sugar control was observed even in the newer INSTI trial.[2]

How Is It Given?

Tesamorelin is injected subcutaneously — meaning just under the skin, typically in the abdomen — once daily.[6] The dose studied in clinical trials is 2 mg per day.[2] Getting the dose right matters, which is why tools like our calculator exist to help researchers and clinicians work through the numbers clearly.

For a full breakdown of studied dosing protocols, head to the tesamorelin dosage chart.

The Bottom Line

Tesamorelin is one of the most well-studied peptides in clinical medicine, with a clear FDA-approved use and a growing body of research exploring new applications like liver fat reduction. The evidence is strongest for reducing visceral fat in people with HIV-associated lipodystrophy — with two Phase 3 trials and a more recent 2024 study all pointing in the same direction.[2][5][6]

Research is ongoing. As always, this information is educational. Any use of peptides in a research context should follow proper protocols and institutional guidelines.

Sources

  1. Tesamorelin. — , 2012. PMID 31644039.
  2. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. — AIDS (London, England), 2024. PMID 38905488.
  3. Tesamorelin. — Nature reviews. Drug discovery, 2011. PMID 21283099.
  4. Tesamorelin update. — BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2010. PMID 21591600.
  5. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. — Drugs, 2011. PMID 21668043.
  6. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. — The Annals of pharmacotherapy, 2012. PMID 22298602.
See the dosage chart — Tesamorelin
A growth-hormone-releasing hormone analog studied for visceral fat reduction.
Tesamorelin

FAQ

What exactly does tesamorelin do in the body?
Tesamorelin mimics a natural brain hormone called GHRH, which signals the pituitary gland to release growth hormone. That boost in GH activity influences fat metabolism — particularly the breakdown of deep visceral (belly) fat. It doesn't deliver synthetic growth hormone directly; it prompts your own body to release it in a more natural, pulsed pattern.[3][5]
Is tesamorelin FDA approved?
Yes. The FDA approved tesamorelin (brand name Egrifta) in November 2010, making it the first approved treatment specifically for reducing excess abdominal fat in people with HIV-associated lipodystrophy. It remains the only FDA-approved therapy for this indication as of the most recent published research.[3][2]
What happens if you stop taking tesamorelin?
Studies show that the visceral fat reductions gained during treatment are not permanent. When participants stopped taking tesamorelin during the 52-week extension phases of clinical trials, the excess abdominal fat returned. This suggests continuous use is needed to maintain the body composition benefits, which has implications for long-term treatment planning.[5]
Does tesamorelin raise blood sugar levels?
Growth hormone can affect glucose metabolism, so this is closely monitored in studies. Across both the original Phase 3 trials and a 2024 study of patients on modern INSTI-based HIV drugs, tesamorelin did not significantly worsen blood sugar control. Hyperglycemia rates were similar between the tesamorelin and placebo groups in the 2024 trial.[2][6]
For research and educational use only. Not medical advice.